Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Christopher Recknor"'
1
Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)
Autor: Massimo Cristofanilli, Namita Chittoria, Sima Ehsani, Hallgeir Rui, Milana Dolezal, Lisette Stork-Sloots, Femke de Snoo, Christopher Recknor, Vandana Abramson
Publikováno v: Cancer Research. 82:P5-17
Background C-C Chemokine Ligand type-5 (CCR5) is overexpressed in >95% of TNBC and has been correlated with disease progression. Moreover, enhancement of DNA repair signaling by CCR5 activation may contribute to chemotherapy resistance. Therefore, bl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::819d3019609ef01e4bdc72aae25b341c
https://doi.org/10.1158/1538-7445.sabcs21-p5-17-08
Zobrazit plný text záznamu
2
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Autor: Norman B, Gaylis, Angela, Ritter, Scott A, Kelly, Nader Z, Pourhassan, Meenakshi, Tiwary, Jonah B, Sacha, Scott G, Hansen, Christopher, Recknor, Otto O, Yang
Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 75, iss 7
In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b77e1c3b9455084b23ec4ff0e0666ce
https://doi.org/10.1093/cid/ciac226
Zobrazit plný text záznamu
5
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
Autor: Carlos Mautalen, Y.-C. Yang, K Poole, Christopher Recknor, Andreas Grauer, M. A. Bolognese, Graham M. Treece, David A. Hanley, RA Pearson, Tristan Whitmarsh, Andrew H. Gee, Jacques P. Brown, Cesar Libanati, Stefan Goemaere, Maria Rojeski
Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 37(2)
Funder: NIHR Cambridge BRC; Id: http://dx.doi.org/10.13039/501100018956
Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption. The location and loca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aba7093d8d513c362a6e191dd1dbde9
https://pubmed.ncbi.nlm.nih.gov/34738660
Zobrazit plný text záznamu
7
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
Autor: Sudhaker D Rao, Robert R. Recker, Valerie A Ruff, Jahangir Alam, Kathleen A. Taylor, David L. Kendler, Hua Zhou, Christopher Recknor, Jacques P. Brown, John H. Krege, Robert Lindsay, David W Dempster, Thomas E. Melby, Paul D. Miller, E. Michael Lewiecki
Publikováno v: Journal of Bone and Mineral Research. 33:298-306
There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e953df69f3c399897313bc65c08410ce
https://doi.org/10.1002/jbmr.3309
Zobrazit plný text záznamu
8
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study
Autor: Boris Janos, Robert R. Recker, Jahangir Alam, John H. Krege, David W. Dempster, Paul D. Miller, David L. Kendler, Jacques P. Brown, Sudhaker D Rao, E. Michael Lewiecki, Hua Zhou, Christopher Recknor, Kathleen A. Taylor, Robert Lindsay, Valerie A Ruff
Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 101:1353-1363
Context: Denosumab-induced PTH elevation may stimulate early bone formation. Objective: Our objective was to evaluate whether denosumab-induced changes of intact PTH (iPTH) result in early anabolic effects according to histomorphometry and bone turno
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e1bed8c4d45e740d71f0c5e4e56fce4
https://doi.org/10.1210/jc.2015-4181
Zobrazit plný text záznamu
10
Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
Autor: Harry K. Genant, Christopher Recknor, Richard Eastell, Jose R. Zanchetta, Jacques P. Brown, David L. Kendler, Thomas Fuerst, Tony M. Keaveny, Stefan Goemaere, Michael R. McClung, Hoi-Shen Radcliffe, Cesar Libanati, Maria Luisa Brandi, David L. Kopperdahl, Klaus Engelke
Publikováno v: Journal of Bone and Mineral Research
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol 29, iss 1
JOURNAL OF BONE AND MINERAL RESEARCH
In the randomized, placebo-controlled FREEDOM study of women aged 60 to 90 years with postmenopausal osteoporosis, treatment with denosumab once every 6 months for 36 months significantly reduced hip and new vertebral fracture risk by 40% and 68%, re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e746ba05c47d2345e5f82ebd03f3dba2
https://doi.org/10.1002/jbmr.2024
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje